Imfinzi looks flimsy in AstraZeneca’s Phase III head and neck cancer study
Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on platinum-based chemotherapy.